NeurAxis
Logotype for NeurAxis Inc

NeurAxis (NRXS) investor relations material

NeurAxis Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for NeurAxis Inc
Q3 2026 earnings summary9 Nov, 2026

Executive summary

  • Q3 2026 revenue was $2.03M, up 149.9% YoY; IB-Stim deliveries rose 92% as payer coverage broadened following the Category I CPT code’s January 1, 2026 effective date.

  • Gross margin reached 86.6%; net loss was $6.55M, including $4.30M in one-time stock compensation. Substantial doubt about the ability to continue as a going concern remains.

Financial highlights

  • 9M 2026 sales were $5.56M, up 113.9% YoY; gross profit was $4.80M versus $2.18M.

  • Q3 gross profit was $1.76M versus $676K; operating loss was $6.58M and net loss was $6.55M, versus $2.10M and $2.12M, respectively.

  • 9M operating and net losses were $10.44M and $10.39M; adjusted for one-time stock compensation and the prior-year legal settlement, each was $5.8M.

  • Q3 operating expenses were $8.3M; excluding $4.3M of one-time stock compensation, expenses were $4.0M, up 45% YoY.

  • 9M operating cash use was $4.53M; cash was $4.48M at September 30, 2026.

Outlook and guidance

  • Recent payer wins are expected to contribute in Q4, with a more meaningful impact in 2027 as provider implementation and commercial expansion progress.

  • Sales representatives hired for January starts are expected to affect results within 3–4 months; profitability was described as a first-half 2027 possibility.

  • Near-term hiring, market-access, clinical and R&D investment is expected to raise SG&A and cash burn; profitability depends on growth and operating leverage.

  • Medicaid fee-schedule coverage could reach 90% of states and territories by spring 2027, with timing potentially extending to July 1.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next NeurAxis earnings date

Logotype for NeurAxis Inc
Q4 202619 Mar, 2027
NeurAxis
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next NeurAxis earnings date

Logotype for NeurAxis Inc
Q4 202619 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies aimed at addressing chronic and debilitating conditions in both children and adults. The company’s primary product, IB-Stim, utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology to alleviate functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 11 to 18. The company is headquartered in Carmel, Indiana, and its shares are listed on the NYSE American.